Michal Lotem - Concepedia

Author

Michal Lotem

Also Known As

E Davidovitz, Lotem Michal, Lotem, M., M Lotem, M. Lotem, Michal Lotem, Michal Lotem (691790), Michal M. Lotem, R. Marciano

198

Publications

18.3K

Citations

H-Index

Concepts

All Affiliations

Hadassah Medical Center Sheba Medical Center Hebrew University of Jerusalem Merck & Co., Inc., Rahway, NJ, USA (United States)Melanoma Institute Australia

About

Michal Lotem is an author at Hadassah Medical Center specializing in medicine, immunotherapy, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	39	4.7K
2	Cell Biology	9	9	309
3	Health Sciences	8	8	454
4	Allergy	3	3	50
5	Cellular Physiology	1	1	23

Michal Lotem

Publications

17.6K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert, Jacob Schachter, Georgina V. Long, New England Journal of Medicine	2015	5.7K
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma Caroline Robert, L. Thomas, Igor Bondarenko, New England Journal of Medicine	2011	4.4K
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Jacob Schachter, Antoni Ribas, Georgina V. Long, The Lancet Open-label Phase 3MedicineMelanomaImmune Checkpoint InhibitorDermatology	2017	1.2K
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Caroline Robert, Antoni Ribas, Jacob Schachter, The Lancet Oncology MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2019	1.1K
Identification of bacteria-derived HLA-bound peptides in melanoma Shelly Kalaora, Adi Nagler, Deborah Nejman, Nature MedicinePeptide LibraryMelanomaImmunologyMicrobiology	2021	389
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Olga Lyass, Beatrice Uziely, Rami Ben‐Yosef, Cancer	2000	387
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Nature Medicine MedicineMelanomaImmune Checkpoint InhibitorOncologyRadiation Oncology	2019	319
Skin Toxic Effects of Polyethylene Glycol–Coated Liposomal Doxorubicin Michal Lotem, Ayala Hubert, Olga Lyass, Archives of Dermatology	2000	217
Predictors of responses to immune checkpoint blockade in advanced melanoma Nicolas Jacquelot, María P. Roberti, David Enot, Nature Communications	2017	196

Page 1